Sign in Subscribe
Class action lawsuits

Berger Montague Investigates Altimmune Securities Lawsuits

Strategic Insights

— 1 min read

Philadelphia-based law firm Berger Montague PC is investigating claims against Altimmune, Inc. following a class action lawsuit alleging federal securities law violations. Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, may be eligible to seek lead plaintiff representative status. The investigation stems from Altimmune's announcement of topline results from its IMPACT Phase 2b trial, which fell short of expectations, causing a significant decline in stock price.

Key Takeaways:

  • Berger Montague is investigating claims against Altimmune, Inc. for potential federal securities law violations.
  • The investigation follows a class action lawsuit alleging Altimmune made false or misleading statements regarding its IMPACT Phase 2b trial.
  • Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, may be eligible to seek lead plaintiff representative status.
  • Altimmune's stock price declined over 53% in a single day following the announcement of topline results from its IMPACT Phase 2b trial.
  • Berger Montague has represented individual and institutional investors for over five decades and has experience with securities class action litigation.
  • The investigation is ongoing, with an investor deadline of October 6, 2025, to seek appointment as lead plaintiff representative.

Statistics:

  • Altimmune's stock price declined 53% in a single day to $3.61 on June 26, 2025.
  • The IMPACT Phase 2b trial failed to achieve statistical significance in the fibrosis reduction primary endpoint.
  • The trial revealed a higher-than-expected placebo response, citing a Phase 2 nature.
  • Berger Montague has over 50 years of experience in securities class action litigation.

Sources:

  • Berger Montague press release, dated August 19, 2025, citing pseudonym (Newsfile Corp. - August 19, 2025).
  • Berger Montague PC website, detailing firm's experience and practice areas.
  • Altimmune press release, dated June 26, 2025, announcing topline results from IMPACT Phase 2b trial.

Read more